Verve Therapeutics, Inc. financial data

Symbol
VERV on Nasdaq
Industry
Pharmaceutical Preparations
Location
201 Brookline Avenue, Suite 601, Boston, MA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-K - Q4 2024 - Feb 27, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.47K % -4.54%
Debt-to-equity 28.8 % +5.69%
Return On Equity -37.3 % +5.19%
Return On Assets -29 % +6.31%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 88.8M shares +5.75%
Common Stock, Shares, Outstanding 88.8M shares +8.28%
Entity Public Float 345M USD -63.3%
Common Stock, Value, Issued 89K USD +8.54%
Weighted Average Number of Shares Outstanding, Basic 84.7M shares +32%
Weighted Average Number of Shares Outstanding, Diluted 84.7M shares +32%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 204M USD +10.5%
General and Administrative Expense 56.6M USD +13.4%
Operating Income (Loss) -229M USD -2.48%
Nonoperating Income (Expense) 30.3M USD +29.9%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -198M USD +0.72%
Income Tax Expense (Benefit) 349K USD +26.9%
Net Income (Loss) Attributable to Parent -199M USD +0.68%
Earnings Per Share, Basic -2.35 USD/shares +24.7%
Earnings Per Share, Diluted -2.35 USD/shares +24.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 173M USD -16.3%
Marketable Securities, Current 352M USD -15.8%
Cash, Cash Equivalents, and Short-term Investments 524M USD -16%
Assets, Current 543M USD -14.9%
Property, Plant and Equipment, Net 18.6M USD -17.2%
Operating Lease, Right-of-Use Asset 78.1M USD -8.46%
Other Assets, Noncurrent 3.14M USD +45.1%
Assets 647M USD -14%
Accounts Payable, Current 4.52M USD -31.9%
Accrued Liabilities, Current 24.3M USD +20.6%
Liabilities, Current 42.9M USD +16%
Operating Lease, Liability, Noncurrent 59.5M USD -8%
Other Liabilities, Noncurrent 95K USD -49.7%
Liabilities 154M USD +0.53%
Accumulated Other Comprehensive Income (Loss), Net of Tax 428K USD +57.4%
Retained Earnings (Accumulated Deficit) -743M USD -36.5%
Stockholders' Equity Attributable to Parent 493M USD -17.7%
Liabilities and Equity 647M USD -14%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -43.1M USD +12.2%
Net Cash Provided by (Used in) Financing Activities 22.7M USD +1016%
Net Cash Provided by (Used in) Investing Activities -41.6M USD -370%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 88.8M shares +8.28%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -62M USD -95.7%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 177M USD -15.9%
Deferred Tax Assets, Valuation Allowance 229M USD +33%
Deferred Tax Assets, Gross 251M USD +27.8%
Operating Lease, Liability 70M USD -6.57%
Depreciation 6.75M USD +23.8%
Payments to Acquire Property, Plant, and Equipment 433K USD -87.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -199M USD +0.28%
Lessee, Operating Lease, Liability, to be Paid 95.4M USD -10%
Property, Plant and Equipment, Gross 35.8M USD +8.68%
Operating Lease, Liability, Current 10.4M USD +2.45%
Lessee, Operating Lease, Liability, to be Paid, Year Two 11.2M USD +3.15%
Lessee, Operating Lease, Liability, to be Paid, Year One 10.9M USD +3.14%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 25.4M USD -18.4%
Lessee, Operating Lease, Liability, to be Paid, Year Three 11.5M USD +3.14%
Deferred Tax Assets, Operating Loss Carryforwards 57.9M USD +12.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 11.9M USD +3.15%
Operating Lease, Payments 2.64M USD -16.1%
Preferred Stock, Shares Outstanding 0 shares
Deferred Tax Assets, Net of Valuation Allowance 0 USD
Share-based Payment Arrangement, Expense 43.3M USD +23.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%